XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
  Cornea
  Cataract
  Retina
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Ophthalmology Channel
subscribe to Ophthalmology newsletter

Latest Research : Ophthalmology

   DISCUSS   |   EMAIL   |   PRINT
Onchocerciasis treatment reduces prevalence and intensity by 38%
Jul 31, 2006 - 11:45:00 AM, Reviewed by: Dr. Priya Saxena


A project held during more than 10 years by a group from Hospital Cl�nic-Universitat de Barcelona established in Equatorial Guinea studies a disease affecting 18 million people, 17,5 of which live in Africa. Onchocerciasis affects skin, eyes and other organs, usually causing blindness.


 
Onchocerciasis, river blindness or craw craw is an endemic disease in Bioko Island, Equatorial Guinea. This pathology causes a weakening in affected individuals, most of them within the labour force population, making this disease one of the limiting factors for the economic development of the island. Onchocerciasis is caused by the worm Onchocerca volvulus. It is transmitted through the bite of the black fly, Simulium. Enviromental conditions such as humidity, rapid water rivers and altitude of Bioko favour the development of this pathology, since this is the habitat of the fly acting as a vector. The parasite, in the form of larve, is inoculated to humans when the fly bites humans to obtain blood. Female parasites measure 30 to 50 cm and live 10 to 15 years, whereas male parasites measure 3 to 5 cm. Worms form tumours in infected indivuduals, and some of them are easily visible. Fecunded females emit daily 1,200 larves (microfilaria) measuring 150-360 micras, which are disseminated through the host�s skin, eyes and other organs. Affected individuals can host 50-200 million worms, especially distributed in skin and eyes, usually provoking blindness.

The work, carried out by the group of Hospital Cl�nic de Barcelona, was led by Dr. Jordi Mas of the Microbiology Unit of Hospital Cl�nic-Universitat de Barcelona, and Dr. Carlos Ascaso of the IDIBAPS Epidemiology and International Health Research Group. The objective of this study was to assess the impact of 8-year vertical distribution of Ivermectin, the only treatment available against onchocerciasis, among the rural population of 12 communities and two ethnical groups: the Bubis and the Fangs. The fact that the administered drug dose is only effective on larves, conditions the duration of this study. The study was carried out during 8 years, because this is precisely the maximum time of fertility of females, what guarantees the total elimination of the offspring.

This study, published in Tropical Medicine and Internacional Health (11(7):1082-91), has been financed by the Spanish Agency of International Cooperation, and the World Health Organisation (WHO). It continues from the achievements of previous works held in Africa in order to assess Ivermectin effects and to determine the importance of onchocerciasis. Results are highly conclusive in this case: onchocerciasis prevalence before treatment was of 74.5%, and after treatment, 38.4%. Furthermore, we want to underline that after Ivermectin administration, the incidence of onchocerciasis in children aged 0-4 decreased 2.6 times.

The follow-up of this project creeted more than a decade ago by Dr. Jordi Mas continues to be in force by the Ministry of Health of Equatorial Guinea. Nevertheless, the monitoring of the state of the disease is conducted by the Catalan group from Barcelona and Bioko.

Future strategies of the fight against river blindness go further than the administration of Ivermectin. Currently, the vector of the disease is being eliminated by the WHO African Programme for Onchocerciasis (APOC). Dr. Jordi Mas will soon travel to Bioko in order to test the effects of the new measures. The efficiency of these methods, the operation of the project, along with the results of the studies of the Hospital Cl�nic Group will be assessed in the near future in a joint meeting with the Ministry of Health of Equatorial Guinea, the WHO and Dr. Jordi Mas.
 

- Tropical Medicine and Internacional Health (11(7):1082-91),
 

Pubmed Citation

 
Subscribe to Ophthalmology Newsletter
E-mail Address:

 



Related Ophthalmology News

Master Proteins Dictate Retinal Differentiation Timetable
Yellow plant pigments lutein and zeaxanthin reduce risk of age-related macular degeneration
Objective way to diagnose diseases of colour perception
Onchocerciasis treatment reduces prevalence and intensity by 38%
Antioxidants may slow retinal degeneration
Hormone Therapy Does Not Affect Age-Related Vision Loss
Eating Fish Protects Against Macular Degeneration
Research Highlights Risk Factors For Age-Related Vision Loss
How Thalamic Neurons Grab Your Attention
FDA approves ranibizumab for the treatment of wet age-related macular degeneration


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us